Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.27
+8.0%
$7.85
$5.01
$18.71
$51.15M0.18117,786 shs41,364 shs
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$9.98
$0.88
$1.65
$62.85M1.23269,831 shs206,800 shs
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
$31.01
+0.0%
$25.41
$9.59
$29.55
$1.04B2.84185,808 shs1,131 shs
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
$18.99
$18.99
$7.01
$19.30
$655.69MN/A205,753 shsN/A
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
$2.80
-3.1%
$19.37
$0.22
$3.94
$62.10M0.61.11 million shs341,538 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+8.04%+18.85%+0.43%+57.39%+16.46%
AVROBIO, Inc. stock logo
AVRO
AVROBIO
0.00%0.00%0.00%0.00%0.00%
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
-1.46%+0.56%+5.57%+38.23%+16.98%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.00%0.00%0.00%0.00%0.00%
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
-3.11%-7.59%-16.04%-25.33%+35.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.0952 of 5 stars
3.33.00.04.70.62.50.6
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/AN/AN/AN/A
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.57
Moderate Buy$17.7591.48% Upside
AVROBIO, Inc. stock logo
AVRO
AVROBIO
0.00
N/AN/AN/A
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
0.00
N/AN/AN/A
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.00
N/AN/AN/A
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$128.94M0.43N/AN/A($16.89) per share-0.55
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/A$2.13 per shareN/A
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
N/AN/AN/AN/A$5.89 per shareN/A
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/AN/A
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
N/AN/AN/AN/A($0.06) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/A
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
-$36.86M-$1.26N/AN/AN/AN/A-30.89%-27.65%N/A
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/A

Latest NITE, PRTO, ATRA, AVRO, and OSIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/A
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
N/AN/AN/AN/AN/A
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/A
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.57
0.57
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/A
26.17
26.17
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
N/A
8.54
8.54
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/A
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
N/A
5.98
5.98

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
AVROBIO, Inc. stock logo
AVRO
AVROBIO
62.63%
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
32.83%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.28%
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
23.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.72 millionOptionable
AVROBIO, Inc. stock logo
AVRO
AVROBIO
1344.89 million40.76 millionOptionable
Nightstar Therapeutics PLC stock logo
NITE
Nightstar Therapeutics
4733.54 millionN/ANot Optionable
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
34234.53 millionN/ANot Optionable
Proteon Therapeutics Inc stock logo
PRTO
Proteon Therapeutics
1722.18 millionN/ANot Optionable

Recent News About These Companies

ProQR Therapeutics price target raised to $4 from $2.50 at Chardan
Protara Therapeutics (TARA) Earnings Dates & Reports
ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James
ProQR Announces Major Share Offering Agreement
Understanding Neurodegenerative Disease with Prion Research
iPhone 13 Pro vs. iPhone 16 Pro: 65+ Upgrades to Expect
PTC Therapeutics: Q1 Earnings Snapshot
Protara Therapeutics Inc (TARA)
iPad Pro
Esperion Therapeutics Inc ESPR
The Latest Analyst Ratings for Revance Therapeutics
ENLV - Enlivex Therapeutics Ltd.
The best iPhone 14 Pro deals for May 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$9.27 +0.69 (+8.04%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$9.24 -0.03 (-0.32%)
As of 07/8/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

AVROBIO stock logo

AVROBIO NASDAQ:AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Nightstar Therapeutics stock logo

Nightstar Therapeutics NASDAQ:NITE

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Osiris Therapeutics stock logo

Osiris Therapeutics OTCMKTS:OSIR

$18.99 0.00 (0.00%)
As of 04/17/2019

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Proteon Therapeutics stock logo

Proteon Therapeutics NASDAQ:PRTO

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.